Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of MEDI9929 (Tezepelumab) in Adolescents with Asthma
NCT02512900Phase 1Completed
- Sponsor
- MedImmune
- Start
- Sep 2015
- Primary completion
- May 2016
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of tezepelumab in asthma (2 cohorts), sponsored by MedImmune. Primary endpoints: Area Under the Concentration-time Curve From Zero to Infinity at Day 85, Area Under the Concentration-Time Curve From Zero to Last Observation at Day 85 and 7 more. Started Sep 2015; status: completed.
02
Drugs
03
Conditions
asthma
Beyond the preview
Go deeper on NCT02512900.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02512900.